Lyme Disease Vaccine Global Market Report 2025

The Lyme disease vaccine market size has grown strongly in recent years. It will grow from $1.04 billion in 2024 to $1.12 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period resulted from growing human-tick interaction due to habitat expansion, rising healthcare infrastructure in endemic regions, increasing research funding for infectious-disease vaccines, and greater consumer interest in preventive travel or occupational health.

The Lyme disease vaccine market size is expected to see strong growth in the next few years. It will grow to $1.47 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period will be driven by the rising incidence of Lyme disease, growing public health awareness of tick-borne risks, increasing government investment in vaccine development, rising demand for preventive vector-borne disease solutions, and expanding collaboration in biotech for vaccine platforms. Major trends in the forecast period include technological advancements in mRNA and recombinant Lyme vaccines, the integration of Lyme vaccination into routine immunization programs, innovations in multi-pathogen tick-borne disease vaccines, collaborative global vaccine development partnerships, and progress in novel delivery systems.

The growing prevalence of Lyme disease is expected to drive the expansion of the Lyme disease vaccine market in the future. Lyme disease is a tick-borne illness caused by Borrelia bacteria, which can lead to symptoms such as fever, fatigue, rashes, and, if left untreated, severe complications affecting the joints, heart, or nervous system. The rise in Lyme disease cases is largely attributed to climate change, as warmer temperatures and milder winters are expanding tick habitats, thereby increasing human exposure to infected ticks. Lyme disease vaccines help prevent the infection by stimulating the immune system to recognize and fight off Borrelia bacteria, thereby reducing the risk of disease. These vaccines offer long-term protection, which contributes to better public health outcomes. For example, the Centers for Disease Control and Prevention (CDC) reported that in 2023, approximately 89,000 cases of Lyme disease were officially recorded in the U.S., although estimates suggest that nearly 476,000 people may be diagnosed and treated for the disease annually. Thus, the rising prevalence of Lyme disease is fueling the growth of the Lyme disease vaccine market.

Rising healthcare expenditure is also expected to drive growth in the Lyme disease vaccine market. Healthcare expenditure refers to the total amount of financial resources allocated to medical services, treatments, facilities, research, and public health initiatives aimed at improving or maintaining health. The increasing demand for healthcare services is driven by the rising prevalence of chronic diseases that require long-term, costly treatments. The growth in healthcare spending supports the development of Lyme disease vaccines by providing additional funding for research, clinical trials, and production processes. This facilitates the advancement of vaccine technologies, improving both accessibility and effectiveness for high-risk populations. For example, in May 2024, the Office for National Statistics reported that healthcare expenditure in the UK increased by 5.6% in nominal terms in 2023, marking a 0.9% rise from 2022. Consequently, the rise in healthcare expenditure is contributing to the growth of the Lyme disease vaccine market.

Leading companies in the Lyme disease vaccine market are focusing on advancing their late-stage product candidates, including booster vaccines, to meet unmet medical needs, improve immune protection, and streamline vaccination schedules. Booster vaccines are additional doses given after the initial vaccination to enhance or restore long-term immunity. For example, in September 2025, Valneva SE, a France-based biotechnology firm, reported positive results from a Phase 2 study of its Lyme disease vaccine candidate, VLA15. This multivalent vaccine targets OspA proteins on Borrelia bacteria, triggering the immune system to produce antibodies that block bacterial infection when ticks bite. The study demonstrated a strong immune response and a favorable safety profile following a third booster dose, with results consistent with those seen after previous annual booster shots. This suggests that the vaccine can provide continued protection against Lyme disease, with the potential for a yearly pre-exposure booster dose before each Lyme season, making vaccination easier for at-risk individuals.

Major companies operating in the lyme disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Boehringer Ingelheim GmbH, University of Pennsylvania, Elanco Animal Health Incorporated, Elanco Animal Health Incorporated, Zoetis Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Life Inc., Bioveta a.s., Dynavax Technologies Corporation, Valneva SE, MassBiologics of UMass Chan Medical School, Inovio Pharmaceuticals Inc., US Biologic Inc., Blue Lake Biotechnology Inc.

North America was the largest region in the Lyme disease vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in Lyme disease vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Lyme disease vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The Lyme disease vaccine market research report is one of a series of new reports that provides Lyme disease vaccine market statistics, including Lyme disease vaccine industry global market size, regional shares, competitors with a Lyme disease vaccine market share, detailed Lyme disease vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the Lyme disease vaccine industry. This Lyme disease vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lyme disease vaccines are biological preparations developed to stimulate the immune system to identify and combat Borrelia burgdorferi, the bacteria that cause Lyme disease, thereby preventing infection after a tick bite. These vaccines function by prompting the body to produce specific antibodies that neutralize the bacteria, lowering the likelihood of disease transmission and related complications, and serving as an important tool for controlling Lyme disease in regions where it is common.

The key vaccine types for Lyme disease include recombinant vaccines, subunit vaccines, live attenuated vaccines, and others. Recombinant vaccines are created using genetic engineering methods to generate specific proteins (antigens) from Borrelia burgdorferi, the bacteria responsible for Lyme disease. They employ various technologies such as the lymphocytic transformation test, urine antigen testing, immunofluorescent staining, nucleic acid testing, and serological testing, and are intended for age groups including pediatric, adult, and geriatric populations. Distribution channels include hospitals and clinics, pharmacies, government supply, and others, serving end users such as hospitals, clinical laboratories, and additional healthcare settings.

The Lyme disease vaccine market consists of sales of pre-filled syringes, single or multi-dose vials, vaccine kits, storage and delivery equipment, and cold-chain packaging materials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.